Skip to main content
Premium Trial:

Request an Annual Quote

Degussa Corp. to Take Full Control of Proligo

NEW YORK, Aug. 22 – Gilead Sciences is selling its 49 percent interest in oligonucleotides manufacturer Proligo to Degussa Corporation, which currently holds the remaining Proligo shares, the company announced on Wednesday.

The deal, expected to close on Aug. 31, is for $14 million in cash, according to Foster City, Calif.-based Gilead.

Proligo is a joint venture between Gilead and SKW Americas, a subsidiary of Parsippany, NJ-based Degussa. Proligo of Boulder, Colo. sells standard and specialty monomers for oligonucleotide synthesis and probes. Degussa was entitled to purchase Gilead’s interest in Proligo as part of the terms of Gilead’s 1998 merger with NeXstar Pharmaceuticals, which originally formed Proligo in a joint venture with SKW Americas.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.